Amgen's experimental skin disease drug meets main goals in study-February 2024-www.financetom.com

Amgen's experimental skin disease drug meets main goals in study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Amgen's experimental skin disease drug meets main goals in study

Sep 26, 2024 10:01 AM

Sept 24 (Reuters) - Amgen ( AMGN ) said on Tuesday its

experimental drug, rocatinlimab, met the main goals in a late

stage study testing it as a treatment for an inflammatory skin

condition known as atopic dermatitis.

Previous page： Google Cloud COO Diane Bryant quits Next page： Google Doodle honours inventor of first powered vacuum cleaner

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google Cloud COO Diane Bryant quits

Jul 4, 2018

Diane Bryant, a top-level Google Cloud executive who joined the tech giant after serving Intel for 32 years, is moving on.

Google Doodle honours inventor of first powered vacuum cleaner

Jul 4, 2018

To celebrate the invention of a powered vacuum cleaner by Hubert Cecil Booth more than a century ago, Google on Wednesday marked the British engineer's 147th birth anniversary with an interactive Doodle.

Samsung's second-quarter profit seen flagging as smartphone innovation dries up

Jul 4, 2018

Samsung Electronics Co Ltd is expected to post its smallest profit growth in more than a year in the second quarter, as lacklustre sales of its premium Galaxysmartphones overshadow its highly profitable chip business.

Facebook's new feature will tell users how much time they spend on the app, says report

Jul 3, 2018

Social media giant, Facebook, may soon introduce a feature that will show users how much time they had spent on site, reported Tech Crunch.